301166 Stock Overview
Shanghai Universal Biotech Co.,Ltd. distributes and supplies antibodies and protein products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Shanghai Universal Biotech Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥28.40 |
| 52 Week High | CN¥50.39 |
| 52 Week Low | CN¥22.81 |
| Beta | 1.5 |
| 1 Month Change | -7.79% |
| 3 Month Change | -13.36% |
| 1 Year Change | -39.79% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -72.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 301166 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | 1.5% | -0.9% | -0.4% |
| 1Y | -39.8% | -33.5% | -14.4% |
Return vs Industry: 301166 underperformed the CN Healthcare industry which returned -32.4% over the past year.
Return vs Market: 301166 underperformed the CN Market which returned -15.1% over the past year.
Price Volatility
| 301166 volatility | |
|---|---|
| 301166 Average Weekly Movement | 7.9% |
| Healthcare Industry Average Movement | 6.8% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 301166's share price has been volatile over the past 3 months.
Volatility Over Time: 301166's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 737 | Zhaowu Leng | www.univ-bio.com |
Shanghai Universal Biotech Co.,Ltd. distributes and supplies antibodies and protein products. The company offers antibodies, recombinant proteins, detection kits, antigens, and other products, as well as biochemical reagents, molecular biology reagents, and cell biology reagents.
Shanghai Universal Biotech Co.,Ltd. Fundamentals Summary
| 301166 fundamental statistics | |
|---|---|
| Market cap | CN¥2.46b |
| Earnings (TTM) | CN¥40.32m |
| Revenue (TTM) | CN¥1.23b |
61.0x
P/E Ratio2.0x
P/S RatioIs 301166 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301166 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.23b |
| Cost of Revenue | CN¥985.36m |
| Gross Profit | CN¥240.47m |
| Other Expenses | CN¥200.15m |
| Earnings | CN¥40.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 27, 2024
| Earnings per share (EPS) | 0.47 |
| Gross Margin | 19.62% |
| Net Profit Margin | 3.29% |
| Debt/Equity Ratio | 1.4% |
How did 301166 perform over the long term?
See historical performance and comparison